• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses. 2019 Nov 27. doi: 10.1111/irv.12697. [Epub ahead of print] [h=1]Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement.[/h]
Khalaj-Hedayati A[SUP]1[/SUP], Chua CLL[SUP]1[/SUP], Smooker P[SUP]2[/SUP], Lee KW[SUP]1[/SUP].
[h=3]Author information[/h] 1 School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia. 2 Department of Biosciences and Food Technology, School of Science, RMIT University, Bundoora, Victoria, Australia.

[h=3]Abstract[/h] The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen-presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen-presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.
? 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.


[h=4]KEYWORDS:[/h] immunogenicity; influenza vaccine; nanoparticles; subunit vaccine; vaccine delivery

PMID: 31774251 DOI: 10.1111/irv.12697
 
Back
Top Bottom